• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PAVmed Inc. (Amendment)

    10/6/21 2:28:49 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care
    Get the next $PAVM alert in real time by email
    SC 13G/A 1 form_sc13ga.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
     
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 4)*
     
    PAVmed Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    70387R106
    (CUSIP Number)
     
    October 4, 2021
    (Date of Event which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [   ] Rule 13d-1(b)
    [X] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No.: 70387R106
     
     
     
     
     
    1
    NAME OF REPORTING PERSON
     
    Matthew Sirovich
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     
    (a)  [   ]
    (b)  [   ]
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
    2,504,244
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    2,504,244
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,504,244
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    2.9%
    12
    TYPE OF REPORTING PERSON
     
    IN




    CUSIP No.: 70387R106
     
     
     
     
    ITEM 1(a).
    NAME OF ISSUER:
     
     
     
    PAVmed Inc. (the “Issuer”)
     
     
    ITEM 1(b).
    ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
     
     
     
    One Grand Central Plaza
    Suite 4600
    60 E. 42nd Street
    New York, NY 10165
     
     
    ITEM 2(a).
    NAME OF PERSON FILING:
     
     
     
    Matthew Sirovich
     
     
    ITEM 2(b).
    ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
     
     
     
    c/o Scopia Capital Management LP
    152 West 57th Street, 33rd Floor
    New York, NY 10019
     
     
    ITEM 2(c).
    CITIZENSHIP:
     
     
     
    United States
     
     
    ITEM 2(d).
    TITLE OF CLASS OF SECURITIES:
     
     
     
    Common Stock, par value $0.001 per share (“Common Stock”)
     
     
    ITEM 2(e).
    CUSIP NUMBER:
     
     
     
    70387R106
     
    ITEM 3.
    IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
     
     
     
    Not Applicable.


     
     
    ITEM 4.
    OWNERSHIP:
     
     
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
     
     
     
    (a)
    Amount beneficially owned:
     
     
    2,504,244
     
     
     
     
    (b)
    Percent of class:
     
     
    2.9%
     
     
     
     
    (c)
    Number of shares as to which the person has:
     
     
     
     
     
    (i)        Sole power to vote or to direct the vote:

     
     
    2,504,244
     
     
     
     
     
    (ii)       Shared power to vote or to direct the vote:
     
     
    0
     
     
     
     
     
    (iii)      Sole power to dispose or to direct the disposition of:
     
     
    2,504,244
     
     
     
     
     
    (iv)      Shared power to dispose or to direct the disposition of:
     
     
    0
     

    Of the shares of Common Stock reported as beneficially owned herein, The Sirovich Family Charitable Foundation (the “Sirovich Foundation”) directly holds 1,560,338 shares of Common Stock.  Matthew Sirovich is a Director and President of the Sirovich Foundation and may be deemed to beneficially own the shares of Common Stock held by the Sirovich Foundation.  In addition, The Boomer Fund, L.P. (“Boomer”) directly holds 466,000 shares of Common Stock.  Mr. Sirovich is the general partner of Boomer and may be deemed to beneficially own the shares of Common Stock held by Boomer.  Mr. Sirovich directly holds and beneficially owns 477,906 shares of Common Stock.  As of December 31, 2020, Mr. Sirovich also held Series Z Warrants to purchase 458,257 shares of Common Stock and may have been deemed to beneficially own the 857,452 shares of Common Stock underlying the Series Z Warrants held by the Sirovich Foundation and 466,000 shares of Common Stock underlying the Series Z Warrants held by Boomer.  The Series Z Warrants were exercisable upon issuance for an exercise price of $1.60 per share of Common Stock and were set to expire on April 30, 2024. All such Series Z Warrants held by Mr. Sirovich, the Sirovich Foundation and Boomer have been exercised in full for shares of Common Stock.  The percentage of beneficial ownership reported herein is based on 84,767,593 shares of Common Stock outstanding as of August 12, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 16, 2021, plus 1,781,709 shares of Common Stock received upon the exercise of the Series Z Warrants.
     


    ITEM 5.
    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
     
     
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
     
     
    ITEM 6.
    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
     
     
     
    The information in Item 4 is incorporated herein by reference.
     
     
    ITEM 7.
    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
     
     
     
    Not applicable.
     
     
    ITEM 8.
    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

     
     
     
    Not applicable.
     
    ITEM 9.
    NOTICE OF DISSOLUTION OF GROUP:
     
     
     
    Not applicable.
     
     
    ITEM 10.
    CERTIFICATION:
     
     
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.




    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date:  October 6, 2021
     
    /s/ Matthew Sirovich
    MATTHEW SIROVICH
     
     



    Get the next $PAVM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PAVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on PAVmed with a new price target

      Cantor Fitzgerald initiated coverage of PAVmed with a rating of Overweight and set a new price target of $8.00

      3/30/21 6:22:24 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lake Street Capital reiterated coverage on PAVmed with a new price target

      Lake Street Capital reiterated coverage of PAVmed with a rating of Buy and set a new price target of $9.00 from $5.00 previously

      2/22/21 4:33:18 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

      Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing NEW YORK, April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced positive data from a National Cancer Institute (NCI)-sponsored study demonstrating that its EsoGuard® Esophageal DNA Test can effectively detect esophageal precancer (Barrett's Esophagus or BE) among at-risk patients without symptoms of chronic gastroesophageal reflux disease (GERD), such as heartburn. These results support EsoGuard esophageal precancer testing in

      4/24/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Leadership Updates

    Live Leadership Updates

    See more

    $PAVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PAVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

      Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements.  As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain

      9/16/24 4:30:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

      Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing

      5/7/24 7:39:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

      The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with PortIO NEW YORK, March 21, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has launched a wholly owned incubator, PMX, to complete development and commercialization of existing portfolio technologies, including the PortIO™ Implantable Intraosseous Vascular Access Device ("PortIO"), EsoCure™ Esophageal Ablation Device ("EsoCure"), and CarpX® Minimally Inva

      3/21/24 8:30:00 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • New insider Tasso Partners, Llc claimed ownership of 2,574,350 shares (SEC Form 3)

      3 - PAVmed Inc. (0001624326) (Issuer)

      3/14/25 7:53:09 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Agrawal Sundeep

      4 - PAVmed Inc. (0001624326) (Issuer)

      10/23/24 4:36:47 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Agrawal Sundeep

      4 - PAVmed Inc. (0001624326) (Issuer)

      9/20/24 4:13:39 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      11/14/24 10:02:46 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      9/23/24 8:46:15 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      2/14/24 3:38:38 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    SEC Filings

    See more
    • SEC Form DEFA14A filed by PAVmed Inc.

      DEFA14A - PAVmed Inc. (0001624326) (Filer)

      5/9/25 4:00:05 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by PAVmed Inc.

      DEFA14A - PAVmed Inc. (0001624326) (Filer)

      4/30/25 4:17:09 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by PAVmed Inc.

      DEF 14A - PAVmed Inc. (0001624326) (Filer)

      4/30/25 4:15:37 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Financials

    Live finance-specific insights

    See more
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies  Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch  PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet Conference call and webcast to be held today, March 25th, at 8:30 AM EDT NEW YORK, March 25, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital

      3/25/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care